Information Provided By: 
Fly News Breaks for May 10, 2019
VSTM
May 10, 2019 | 05:02 EDT
Raymond James analyst Reni Benjamin downgraded Verastem to Market Perform from Outperform citing the company's "lackluster" launch and guidance.
News For VSTM From the Last 2 Days
VSTM
Apr 18, 2024 | 16:05 EDT
Verastem Oncology "announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company's clinical and medical strategy. Dr. Hayslip succeeds Louis J. Denis, M.D., who recently departed the company. Dr. Hayslip has more than 25 years of oncology and research and development experience across industry and academia, most recently serving as the chief medical officer at I-MAB Biopharma. "
